Cited by 3,617Lung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer

Open access

Paz-Ares, Luis, Luft, Alexander, Vicente, David, Tafreshi, Ali, Gümüş, Mahmut, Mazières, Julien, Hermes, Barbara, Çay Şenler, Filiz, Csőszi, Tibor, Fülöp, Andrea, Rodríguez-Cid, Jerónimo, Wilson, Jonathan, Sugawara, Shunichi, Kato, Terufumi, Lee, Ki Hyeong, Cheng, Ying, Novello, Silvia, Halmos, Balazs, Li, Xiaodong, Lubiniecki, Gregory M., Piperdi, Bilal, Kowalski, Dariusz M.·2018·New England Journal of Medicine

DOI 10.1056/nejmoa1810865

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. METHODS: In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free survival. RESULTS: After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence interval [CI], 13.2 to not reached) in the pembrolizumab-combination group and 11.3 months (95% CI, 9.5 to 14.8) in the placebo-combination group (hazard ratio for death, 0.64; 95% CI, 0.49 to 0.85; P<0.001). The overall survival benefit was consistent regardless of the level of PD-L1 expression. The median progression-free survival was 6.4 months (95% CI, 6.2 to 8.3) in the pembrolizumab-combination group and 4.8 months (95% CI, 4.3 to 5.7) in the placebo-combination group (hazard ratio for disease progression or death, 0.56; 95% CI, 0.45 to 0.70; P<0.001). Adverse events of grade 3 or higher occurred in 69.8% of the patients in the pembrolizumab-combination group and in 68.2% of the patients in the placebo-combination group. Discontinuation of treatment because of adverse events was more frequent in the pembrolizumab-combination group than in the placebo-combination group (13.3% vs. 6.4%). CONCLUSIONS: In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp & Dohme; KEYNOTE-407 ClinicalTrials.gov number, NCT02775435 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1810865

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citation
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citation
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citation
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citation
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citation
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Self-citation
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Self-citation
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Self-citation

Flagged first, then by citations

Show all 26 references

Sorted by citations

Items 101–200 of 1,006

A review of glioblastoma immunotherapy
Medikonda, R. T., Dunn, G. P., Rahman, M., Fecci, P. E., & Lim, M. K. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03448-1 · Cited by 307
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
Kostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze‐Koops, H., Choy, E., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 307
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers
Wallis, C. J. D., Butaney, M., Satkunasivam, R., Freedland, S. J., Patel, S. P., Hamid, O., Pal, S. K., & Klaassen, Z. W. A. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5904 · Cited by 294
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 296
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
Niu, J., Maurice‐Dror, C., Lee, D. H., Kim, D.-W., Nagrial, A. M., Voskoboynik, M., Chung, H. C., Mileham, K. F., Vaishampayan, U. N., Rasco, D. W., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.11.002 · Cited by 288
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Sholl, L. M., Hirsch, F. R., Hwang, D. M., Botling, J., López‐Ríos, F., Bubendorf, L., Mino-Kenudson, M. A., Roden, A. C., Beasley, M. B., Borczuk, A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.019 · Cited by 286
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
Lu, S., Wang, J., Yu, Y., Yu, X., Hu, Y., Ai, X., Ma, Z., Li, X., Zhuang, W., Liu, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.005 · Cited by 284
Self-citation
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Liu, J., Yang, Y., Liu, Z., Fu, X., Cai, X., Li, H., Zhu, L., Shen, Y., Zhang, H., Sun, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004291 · Cited by 287
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study
Herbst, R. S., Garon, E. B., Kim, D., Cho, B. C., Perez‐Gracia, J. L., Han, J., Arvis, C. D., Majem, M., Forster, M. D., Monnet, I., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02446 · Cited by 288
Self-citation
Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients
Duffy, M. J., & Crown, J. P. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2019.303644 · Cited by 280
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer
Jabbour, S. K., Lee, K. H., Frost, N., Breder, V. V., Kowalski, D. M., Pollock, T. W., Levchenko, E., Reguart, N., Martínez‐Martí, A., Houghton, B., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2301 · Cited by 281
Self-citation
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial
Qin, J., Xue, L., Hao, A., Guo, X., Jiang, T., Ni, Y., Liu, S., Chen, Y., Jiang, H., Zhang, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03064-w · Cited by 273
Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer
Fournel, L., Wu, Z., Stadler, N., Damotte, D., Lococo, F., Boulle, G., Ségal-Bendirdjian, E., Bobbio, A., Icard, P., Trédaniel, J., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.08.005 · Cited by 249
Checkpoint inhibitor immunotherapy in kidney cancer
Xu, W. V., Atkins, M. B., & McDermott, D. F. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0282-3 · Cited by 267
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
Genova, C., Dellepiane, C., Carrega, P., Sommariva, S., Ferlazzo, G., Pronzato, P., Gangemi, R. M. R., Filaci, G., Coco, S., & Croce, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799455 · Cited by 273
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Grant, M. J., Herbst, R. S., & Goldberg, S. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00520-1 · Cited by 257
VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment
Zhao, Y., Guo, S., Deng, J. M., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., Chen, M., Li, X., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70958 · Cited by 265
Self-citation
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
Boyer, M. J., Şendur, M. A. N., Rodríguez‐Abreu, D., Park, K., Lee, D. H., Çiçin, İ., Yumuk, P. F., Orlandi, F., Leal, T. A. B., Molinier, O., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03579 · Cited by 253
Self-citation
Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells
Gannon, H., Zou, T., Kießling, M. K., Gao, G. F., Cai, D., Choi, P. S., Ivan, A. P., Buchumenski, I., Berger, A. C., Goldstein, J. T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07824-4 · Cited by 250
Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review
Käsmann, L., Dietrich, A., Staab-Weijnitz, C. A., Manapov, F., Behr, J., Rimner, A., Jeremic, B. M., Senan, S., Ruysscher, D. D., Lauber, K., et al. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01654-9 · Cited by 256
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
Schoenfeld, J. D., Giobbie‐Hurder, A., Ranasinghe, S., Kao, K. Z., Lako, A., Tsuji, J., Liu, Y., Brennick, R. C., Gentzler, R. D., Lee, C. B., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00658-6 · Cited by 251
Thermal immuno-nanomedicine in cancer
Yang, Z., Gao, D., Zhao, J., Yang, G., Guo, M., Wang, Y., Ren, X., Kim, J. S., Jin, L., Tian, Z., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00717-y · Cited by 255
Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
Liu, R., Oldham, R. J., Teal, E. L., Beers, S. A., & Cragg, M. S. (2020) · Antibodies · doi:10.3390/antib9040064 · Cited by 248
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
Zhou, C., Wang, Z., Sun, Y., Cao, L., Ma, Z., Wu, R., Yu, Y., Yao, W., Chang, J., Chen, J., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00650-1 · Cited by 238
The cutting-edge progress of immune-checkpoint blockade in lung cancer
Zhou, F., Qiao, M., & Zhou, C. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00577-5 · Cited by 239
Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study
Qian, D. C., Kleber, T., Brammer, B., Xu, K. M., Switchenko, J. M., Janopaul-Naylor, J. R., Zhong, J., Yushak, M. L., Harvey, R. D., Paulos, C. M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00546-5 · Cited by 229
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
Dafni, U. G., Tsourti, Z., Vervita, K., & Peters, S. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.029 · Cited by 226
Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
Birzu, C., French, P. J., Caccese, M., Cerretti, G., Idbaïh, A., Zagonel, V., & Lombardi, G. (2020) · Cancers · doi:10.3390/cancers13010047 · Cited by 229
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC
Jassem, J., de Marinis, F., Giaccone, G., Vergnenégre, A., Barrios, C. H., Morise, M., Felip, E., Oprean, C. M., Kim, Y., Andric, Z. G., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.019 · Cited by 222
Rational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 221
Squamous cell lung cancer: Current landscape and future therapeutic options
Lau, S. C. M., Pan, Y., Velcheti, V., & Wong, K. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.018 · Cited by 215
Immune Checkpoint Inhibitor Therapy in Oncology
Tan, S., Day, D., Nicholls, S. J., & Segelov, E. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.09.004 · Cited by 219
Precision Management of Advanced Non–Small Cell Lung Cancer
Yang, C., Yang, J. C., & Yang, P. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051718-013524 · Cited by 212
Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches
Uprety, D., Mandrekar, S. J., Wigle, D. A., Roden, A. C., & Adjei, A. A. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.020 · Cited by 204
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
Leonetti, A., Wever, B. M. M., Mazzaschi, G., Assaraf, Y. G., Rolfo, C. D., Quaini, F., Tiseo, M., & Giovannetti, E. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100644 · Cited by 202
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
Ai, L., Chen, J., Yan, H., He, Q., Luo, P., Xu, Z., & Yang, X. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s267433 · Cited by 217
Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
Egen, J. G., Ouyang, W., & Wu, L. C. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.010 · Cited by 198
Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer
Judd, J., Karim, N. A., Khan, H., Naqash, A. R., Baca, Y., Xiu, J., VanderWalde, A. M., Mamdani, H. M., Raez, L. E., Nagasaka, M., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0201 · Cited by 209
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Self-citation
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
Sugawara, S., Lee, J.-S., Kang, J., Kim, H. R., Inui, N., Hida, T., Lee, K. H., Yoshida, T., Tanaka, H., Yang, C., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.004 · Cited by 195
Self-citation
Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis
Sun, L., Zhang, L., Yu, J., Zhang, Y., Pang, X., Ma, C., Shen, M., Ruan, S., Wasan, H. S., & Qiu, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-58674-4 · Cited by 192
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Ravi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01355-5 · Cited by 201
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
Reck, M., Ciuleanu, T., Cobo, M., Schenker, M., Żurawski, B. A., Menezes, J. J. D., Richardet, E., Bennouna, J., Felip, E., Juan, Ó., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100273 · Cited by 192
Self-citation
Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance
Ashrafi, A., Akter, Z., Modareszadeh, P., Modareszadeh, P., Berisha, E., Alemi, P. S., Castro, M. D. C. C., Deese, A. R., & Li, Z. (2022) · Cancers · doi:10.3390/cancers14194562 · Cited by 200
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
Griesinger, F., Curigliano, G., Thomas, M., Subbiah, V., Baik, C. S., Tan, D. S. W., Lee, D., Misch, D., Garralda, E., Kim, D.-W., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.002 · Cited by 186
Self-citation
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407
Powell, S. F., Rodríguez‐Abreu, D., Langer, C. J., Tafreshi, A., Paz-Ares, L. G., Kopp, H., Rodríguez‐Cid, J. R., Kowalski, D. M., Cheng, Y., Kurata, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.020 · Cited by 188
Self-citation
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
Gaynor, N., Crown, J. P., & Collins, D. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.016 · Cited by 185
Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy
Wang, Z., Little, N., Chen, J., Lambesis, K. T., Le, K. T., Han, W., Scott, A. J., & Lu, J. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00950-z · Cited by 184
Biomarkers of response to PD-1 pathway blockade
Li, H., van der Merwe, P. A., & Sivakumar, S. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01743-4 · Cited by 195
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 213
Management of Brain Metastases in Non–Small-Cell Lung Cancer
Ernani, V., & Stinchcombe, T. E. (2019) · Journal of Oncology Practice · doi:10.1200/jop.19.00357 · Cited by 189
Current issues and perspectives in PD-1 blockade cancer immunotherapy
Chamoto, K., Hatae, R., & Honjo, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01588-7 · Cited by 188
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
Onoi, K., Chihara, Y., Uchino, J., Shimamoto, T., Morimoto, Y., Iwasaku, M., Kaneko, Y., Yamada, T., & Takayama, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051362 · Cited by 183
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)
Wang, Z., Wu, L., Li, B., Cheng, Y., Li, X., Wang, X., Han, L., Wu, X., Fan, Y., Yu, Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00727 · Cited by 186
Self-citation
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
Corte, C. M. D., Sen, T., Gay, C. M., Ramkumar, K., Diao, L., Cardnell, R. J., Rodriguez, B. L., Stewart, C. A., Papadimitrakopoulou, V. A., Gibson, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.009 · Cited by 181
Chemo-Immunotherapy: A New Trend in Cancer Treatment
Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., González, A. P., Martínez‐Pérez, A., Rodrigo, J. P., Garcia-Pedrero, J. M., & Gonzalez, S. R. (2023) · Cancers · doi:10.3390/cancers15112912 · Cited by 192
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
Lee, J. B., Kim, H. R., & Ha, S. (2022) · Immune Network · doi:10.4110/in.2022.22.e2 · Cited by 175
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
Majem, M., Juan, Ó., Insa, A., Reguart, N., Trigo, J. M., Carcereny, E., García‐Campelo, R., García, Y. G., Guirado, M., & Provencio, M. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1978-1 · Cited by 178
Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Markham, M. J., WACHTER, K., Agarwal, N., Bertagnolli, M. M., Chang, S. M., Dale, W., Diefenbach, C., Galindo, C. R., George, D. J., Gilligan, T. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03141 · Cited by 181
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Shi, K., Wang, G., Pei, J., Zhang, J., Wang, J., Ouyang, L., Wang, Y., & Li, W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01311-6 · Cited by 174
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 185
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
Cook, S., Samuel, V., Meyers, D. E., Stukalin, I., Litt, I., Sangha, R. S., Morris, D. G., Heng, D. Y. C., Pabani, A., Dean, M. L., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.52302 · Cited by 182
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
Remón, J., Passiglia, F., Ahn, M., Barlési, F., Forde, P. M., Garon, E. B., Gettinger, S. N., Goldberg, S. B., Herbst, R. S., Horn, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.006 · Cited by 171
Self-citation
NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis
Lurienne, L., Cervesi, J., Duhalde, L., de Gunzburg, J., Andremont, A., Zalcman, G., Buffet, R., & Bandinelli, P.-A. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.002 · Cited by 174
Immune Escape Mechanisms in Non Small Cell Lung Cancer
Anichini, A., Perotti, V., Sgambelluri, F., & Mortarini, R. (2020) · Cancers · doi:10.3390/cancers12123605 · Cited by 174
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study
Santoni, M., Rizzo, A., Mollica, V., Matrana, M. R., Rosellini, M., Faloppi, L., Marchetti, A., Battelli, N., & Massari, F. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103596 · Cited by 169
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
Xiong, A., Wang, L., Chen, J., Wu, L., Liu, B., Yao, J., Zhong, H., Li, J., Cheng, Y., Sun, Y., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02722-3 · Cited by 173
Self-citation
The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials
written on behalf of AME Lung Cancer Collaborative Group, Xu, Y., Wan, B., Chen, X., Zhan, P., Zhao, Y., Zhang, T., Liu, H., Afzal, M. Z., Dermime, S., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.08.09 · Cited by 170
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
Nowak, A. K., Lesterhuis, W. J., Kok, P., Brown, C. S. B., Hughes, B. G. M., Karikios, D. J., John, T., Kao, S. C.-H., Leslie, C., Cook, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30462-9 · Cited by 167
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
Middleton, G., Brock, K., Savage, J. S., Mant, R., Summers, Y., Conibear, J., Shah, R. N. H., Ottensmeier, C. H. H., Shaw, P. H., Lee, S. M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30033-3 · Cited by 168
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
Yang, J. C., Lee, D. H., Lee, J., Fan, Y., de Marinis, F., Iwama, E., Inoue, T., Rodríguez‐Cid, J. R., Zhang, L., Yang, C., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02747 · Cited by 165
Self-citation
Tumour mutational burden: clinical utility, challenges and emerging improvements
Budczies, J., Kazdal, D. N., Menzel, M., Beck, S., Kluck, K., Altbürger, C., Schwab, C., Allgäuer, M., Ahadova, A., Kloor, M., et al. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00932-9 · Cited by 187
Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association
Beavers, C. J., Rodgers, J. E., Bagnola, A. J., Beckie, T. M., Campia, U., Palo, K. E. D., Okwuosa, T. M., Przespolewski, E. R., & Sj, D. (2022) · Circulation · doi:10.1161/cir.0000000000001056 · Cited by 170
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study
Mollica, V., Rizzo, A., Marchetti, A., Tateo, V., Tassinari, E., Rosellini, M., Massafra, R., Santoni, M., & Massari, F. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01159-1 · Cited by 163
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study
Dietel, M., Савелов, Н. А., Salanova, R., Micke, P., Bigras, G., Hida, T., López, J. R. A., Skov, B. G., Hutarew, G., Sua, L. F., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.012 · Cited by 163
Self-citation
Open-label, Phase I Study of Nivolumab Combined with nab -Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Wainberg, Z. A., Höchster, H. S., Kim, E. J.-H., George, B., Kaylan, A., Chiorean, E. G., Waterhouse, D. M., Guiterrez, M., Parikh, A. R., Jain, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0099 · Cited by 162
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
Brueckl, W. M., Ficker, J. H., & Zeitler, G. (2020) · BMC Cancer · doi:10.1186/s12885-020-07690-8 · Cited by 159
Tracking Cancer Evolution through the Disease Course
Bailey, C., Black, J. R., Reading, J. L., Litchfield, K., Turajlic, S., McGranahan, N., Jamal‐Hanjani, M., & Swanton, C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1559 · Cited by 159
Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action
Xue, Y., Gao, S., Gou, J., Yin, T., He, H., Wang, Y., Zhang, Y. X., Tang, X., & Wu, R. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1825376 · Cited by 159
Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy
Liu, J., Zhao, Z., Qiu, N., Zhou, Q., Wang, G., Jiang, H., Piao, Y., Zhou, Z., Tang, J., & Shen, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-22407-6 · Cited by 154
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out
Proto, C., Ferrara, R., Signorelli, D., Russo, G. L., Galli, G., Imbimbo, M., Prelaj, A., Zilembo, N., Ganzinelli, M., Pallavicini, L. M., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.03.004 · Cited by 158
Emerging therapies for non-small cell lung cancer
Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 159
Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer
Opzoomer, J. W., Sosnowska, D., Anstee, J. E., Spicer, J. F., & Arnold, J. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01654 · Cited by 155
Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer
Ricciuti, B., Recondo, G., Spurr, L. F., Li, Y. Y., Lamberti, G., Venkatraman, D., Umeton, R., Cherniack, A. D., Nishino, M., Sholl, L. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3529 · Cited by 154
Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy
Wen, S., Wang, G., Zhang, Y., Bu, F., Zhang, S., Miller, D. D., Li, W., Ouyang, L., & Wang, Y. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00100 · Cited by 155
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study
Rizzo, A., Santoni, M., Mollica, V., Logullo, F. O., Rosellini, M., Marchetti, A., Faloppi, L., Battelli, N., & Massari, F. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.2029405 · Cited by 151
Colorectal cancer immunotherapy-Recent progress and future directions
Zhao, W., Jin, L., Chen, P., Li, D., Gao, W., & Dong, G. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215816 · Cited by 159
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
Santoni, M., Rizzo, A., Kucharz, J., Mollica, V., Rosellini, M., Marchetti, A., Tassinari, E., Monteiro, F. S. M., Soares, A., Molina‐Cerrillo, J., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03349-4 · Cited by 151
PD-1/PD-L1 Inhibitors in Cervical Cancer
Liu, Y., Wu, L., Tong, R., Yang, F., Yin, L., Li, M., You, L., Xue, J., & Lü, Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00065 · Cited by 153
Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics
Miyauchi, S., Kim, S. S., Pang, J., Gold, K. A., Gutkind, J. S., Califano, J. A., Mell, L. K., Cohen, E. E. W., & Sharabi, A. B. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0871 · Cited by 151
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study
Yang, Y., Sun, J., Wang, Z., Fang, J., Yu, Q., Han, B., Cang, S., Chen, G., Mei, X., Yang, Z., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.015 · Cited by 151
Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)
Zhao, W., Lei, J., Ke, S., Chen, Y., Xiao, J., Wang, L., Wang, L., Ren, Y., Alnaggar, M., Qiu, H., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102315 · Cited by 156
Combination therapy with PD-1 or PD-L1 inhibitors for cancer
Hayashi, H., & Nakagawa, K. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01548-1 · Cited by 144
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
Gray, J. E., Saltos, A. N., Tanvetyanon, T., Haura, E. B., Creelan, B., Antonia, S. J., Shafique, M. R., Zheng, H., Dai, W., Saller, J. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1305 · Cited by 140
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
Facchinetti, F., Mazzaschi, G., Barbieri, F., Passiglia, F., Mazzoni, F., Berardi, R., Proto, C., Cecere, F. L., Pilotto, S., Scotti, V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.023 · Cited by 145
Self-citation
An update on the immune landscape in lung and head and neck cancers
Carlisle, J. W., Steuer, C. E., Owonikoko, T. K., & Saba, N. F. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21630 · Cited by 144
Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
Li, J., Chen, Y., Li, Y., Liu, N., & Ma, J. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01317-7 · Cited by 149
Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement
Sears, C. R., Peikert, T., Possick, J. D., Naidoo, J., Nishino, M., Patel, S. P., Camus, P., Gaga, M., Garon, E. B., Gould, M. K., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201906-1202st · Cited by 143
Immunotherapies and Combination Strategies for Immuno-Oncology
Barbari, C., Fontaine, T., Parajuli, P., Lamichhane, N., Jakubski, S., Lamichhane, P., & Deshmukh, R. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145009 · Cited by 145
Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer
Waterhouse, D. M., Lam, J., Betts, K. A., Yin, L., Gao, S. W., Yuan, Y., Hartman, J., Rao, S. A., Lubinga, S. J., & Stenehjem, D. D. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.04.007 · Cited by 144

Authors: Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., Rodríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K. H., Cheng, Y., Novello, S., Halmos, B., Li, X., Lubiniecki, G. M., Piperdi, B., & Kowalski, D. M.
Affiliations: Université Toulouse III - Paul Sabatier (FR)
From Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center, Universidad Complutense and Ciberonc, Madrid (L.P.-A.), and Hospital Universitario Virgen Macarena, Seville (D.V.) — both in Spain; Leningrad Regional Clinical Hospital, St. Petersburg, Russia (A.L.); Wollongong Oncology and Wollongong Private Hospital, Wollongong, NSW, Australia (A.T.); Istanbul Medeniyet University Hospital, Istanbul (M.G.), and Ankara University, Ankara (F.Ç.Ş.) — both in Turkey; Centre...
Ankara University (TR)
ORCID: Paz-Ares, Luis
Vicente, David
Tafreshi, Ali
Gümüş, Mahmut
Mazières, Julien
Csőszi, Tibor
Sugawara, Shunichi
Kato, Terufumi
Lee, Ki Hyeong
Cheng, Ying
Novello, Silvia
Li, Xiaodong
Piperdi, Bilal
Kowalski, Dariusz M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2018-11-22
Volume: 379
Issue: 21
Pages: 2040-2051
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1810865
OpenAlex: W2892640821
Cited by: 3,617
References: 26
Citations by year: 2026: 220 · 2025: 328 · 2024: 445 · 2023: 440 · 2022: 565 · 2021: 630 · 2020: 606 · 2019: 361 · 2018: 16
FWCI: 303.84
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
HAL (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
Funders: Merck (N/A)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: pembrolizumab, lung squamous cell carcinoma, metastatic lung cancer, PD-L1 expression, immune checkpoint inhibitors, carboplatin, paclitaxel, nab-paclitaxel, first-line therapy, overall survival, progression-free survival, immune-related adverse events, treatment discontinuation, chemoimmunotherapy, PD-1 inhibitors
MeSH terms: Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Carboplatin, Paclitaxel, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks